Výsledky vyhledávání

Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

Autor: P Eisenberg, S. Van Belle, S. Laws, B Osterwalder, H-U Burger, V Moiseyenko, S M O'Reilly, D Melnychuk, E Alba Conejo, T Pienkowski, Stephen P. Ackland, D C Talbot

Publikováno v: British Journal of Cancer

Capecitabine, an oral fluoropyrimidine carbamate, was designed to generate 5-fluorouracil preferentially at the tumour site. This randomised, phase II trial evaluated the efficacy and safety of capecitabine or paclitaxel in patients with anthracyclin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab34cd25db751433232ec1b29efa3547
http://europepmc.org/articles/PMC2375384

Zobrazit plný text záznamu

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

Autor: Jm M. Davies, David Farrugia, L. Medley, An N. Morel, Rv V. Thakker, N. Hayward, Oksana Kirichek, Nicholas Reed, D C Talbot

Publikováno v: British Journal of Cancer

Background:This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).Methods:Multicentre phase II, first-line study design. Oral capecitabine wa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fd69fcc797d10a83d8af7365cc17d63
http://ora.ox.ac.uk/objects/uuid:96a9027e-387a-4d7e-9dce-3bf078b734d2

Zobrazit plný text záznamu

Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer

Autor: S. Ashley, D C Talbot, Alan Hilary Calvert, I. E. Smith, Ian Judson, Janine Mansi

Publikováno v: Journal of Clinical Oncology. 9:2141-2147

Thirty-one patients with advanced breast cancer were treated with CI941, an anthrapyrazole structurally related to mitoxantrone. Patients had not previously been treated with anthracyclines or mitoxantrone, and 15 patients had not received any previo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81c39fa0a70122cda5344b8ab3aa787e
https://doi.org/10.1200/jco.1991.9.12.2141

Zobrazit plný text záznamu

Teicoplanin compared to flucloxacillin for antibiotic treatment of neutropenic patients

Autor: J Large, L Ellis, F Da Costa, B. Jameson, Sam Milliken, D C Talbot, R. L. Powles, S Benjamin, Martin Gore, Smith C

Publikováno v: British Journal of Haematology. 76:6-9

Ninety-eight neutropenic patients were randomized to receive piperacillin and gentamicin in combination with either teicoplanin or flucloxacillin. Sixty-seven of these patients, most of whom had myeloma, were given this combination as prophylaxis 5 d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baeb1047a20b0de864aa1a8e486e1ec1
https://doi.org/10.1111/j.1365-2141.1990.tb07927.x

Zobrazit plný text záznamu

Signet-ring cell lymphoma of bone marrow

Autor: Ian E. Smith, J H Davies, K A Maclennan, D C Talbot

Publikováno v: Journal of Clinical Pathology. 47:184-186

A case of signet-ring cell lymphoma affecting bone marrow is reported. The tumour presented as multiple lytic lesions in the lumbosacral spine. A bone biopsy specimen showed the typical appearances of signet-ring cell lymphoma, and the cells stained

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ada6c442325e912b10d66be2183393a5
https://doi.org/10.1136/jcp.47.2.184

Zobrazit plný text záznamu

Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer

Autor: N C, Levitt, F A, Eskens, K J, O'Byrne, D J, Propper, L J, Denis, S J, Owen, L, Choi, J A, Foekens, S, Wilner, J M, Wood, M, Nakajima, D C, Talbot, W P, Steward, A L, Harris, J, Verweij

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 7(7)

This Phase I study of MMI270, an p.o. administered matrix metalloproteinase inhibitor, assessed toxicity, pharmacokinetics, and tumor response data and investigated markers of biological activity to recommend a dose for Phase II studies. MMI270 was a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b2d231d37f86b6c78040c69fd3879699
https://pubmed.ncbi.nlm.nih.gov/11448904

Zobrazit plný text záznamu

Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours

Autor: R. Lodi, W. C. J. Collins, Peter Styles, J. A. Cramer, Jeremy P Braybrooke, N C Levitt, D C Talbot, Al Harris, David Propper, Trivadi S. Ganesan, Doris J. Taylor

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 10(8)

ANovartisPharmaAG, Basle, Switzerland Summary Background: MKT 077 is a rhodacyanine dye analogue which preferentially accumulates in tumour cell mitochondria. It is cytotoxic to a range of tumours. In this phase I study, MKT 077 was administered as a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::000f060307b56cbfc8950b470474b2ba
https://pubmed.ncbi.nlm.nih.gov/10509153

Zobrazit plný text záznamu

Phase II trial of UFT in advanced colorectal and gastric cancer

Autor: D C Talbot, R. Osborne, Maurice L. Slevin, Rodney H. Reznek, P. I. Clarke, Peter F. M. Wrigley, S. T. A. Malik

Publikováno v: British Journal of Cancer

A phase II trial of continuous oral therapy with UFT, a combination of uracil and the 5-fluorouracil analogue 1-(2-tetrahydrofuryl)-5-fluorouracil (Futraful, Ftorafur), was conducted in 40 patients with advanced colorectal cancer and 18 patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af9796a12c5e34312468b5c7c6e6a6f6
https://doi.org/10.1038/bjc.1990.431

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání